Evofem Biosciences, Inc. (EVFM) stock
EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
$0.01−0.00 (-10.00%)
Close on Oct 19, 2026Market cap $865.23KP/E –Yield –
Evofem Biosciences total assets
Total assets on the balance sheet at the end of each period.
Evofem Biosciences's total assets was $7.52M at Jun 30, 2026. For fiscal 2025 it was $20.27M, down 14.8% from the year before. Over ten years it grew -6.6% a year on average. The highest annual figure on record is $109.97M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.27M | -14.8% |
| FY2024 | Dec 31, 2024 | $23.79M | +125.4% |
| FY2023 | Dec 31, 2023 | $10.55M | -58.1% |
| FY2022 | Dec 31, 2022 | $25.16M | -40.8% |
| FY2021 | Dec 31, 2021 | $42.51M | -61.3% |
| FY2020 | Dec 31, 2020 | $109.97M | +288.6% |
| FY2019 | Dec 31, 2019 | $28.30M | +605.6% |
| FY2018 | Dec 31, 2018 | $4.01M | +1.5% |
| FY2017 | Dec 31, 2017 | $3.95M | -69.2% |
| FY2016 | Dec 31, 2016 | $12.82M | -68.0% |
| FY2015 | Dec 31, 2015 | $40.11M | -47.8% |
| FY2014 | Dec 31, 2014 | $76.90M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $7.52M | -47.7% |
| Q1 FY2026 | Mar 31, 2026 | $7.44M | -42.2% |
| Q4 FY2025 | Dec 31, 2025 | $20.27M | -14.8% |
| Q3 FY2025 | Sep 30, 2025 | $13.81M | -42.3% |
| Q2 FY2025 | Jun 30, 2025 | $14.38M | +68.2% |
| Q1 FY2025 | Mar 31, 2025 | $12.88M | +56.7% |
| Q4 FY2024 | Dec 31, 2024 | $23.79M | +125.4% |
| Q3 FY2024 | Sep 30, 2024 | $23.94M | +70.1% |
| Q2 FY2024 | Jun 30, 2024 | $8.55M | -67.2% |
| Q1 FY2024 | Mar 31, 2024 | $8.22M | -67.3% |
| Q4 FY2023 | Dec 31, 2023 | $10.55M | -75.0% |
| Q2 FY2023 | Jun 30, 2023 | $14.07M | -73.7% |
| Q1 FY2023 | Mar 31, 2023 | $26.03M | -24.7% |
| Q4 FY2022 | Dec 31, 2022 | $25.16M | -40.8% |
| Q3 FY2022 | Sep 30, 2022 | $42.28M | -37.3% |
| Q2 FY2022 | Jun 30, 2022 | $53.47M | -50.8% |
| Q1 FY2022 | Mar 31, 2022 | $34.57M | -63.0% |
| Q4 FY2021 | Dec 31, 2021 | $42.51M | -61.3% |
| Q3 FY2021 | Sep 30, 2021 | $67.43M | -40.0% |
| Q2 FY2021 | Jun 30, 2021 | $108.75M | -19.5% |
| Q1 FY2021 | Mar 31, 2021 | $93.46M | +497.4% |
| Q4 FY2020 | Dec 31, 2020 | $109.97M | +288.6% |
| Q3 FY2020 | Sep 30, 2020 | $112.33M | +188.1% |
| Q2 FY2020 | Jun 30, 2020 | $135.06M | +148.2% |
| Q1 FY2020 | Mar 31, 2020 | $15.65M | +383.8% |
| Q4 FY2019 | Dec 31, 2019 | $28.30M | +605.6% |
| Q3 FY2019 | Sep 30, 2019 | $38.99M | +159.5% |
| Q2 FY2019 | Jun 30, 2019 | $54.42M | +107.9% |
| Q1 FY2019 | Mar 31, 2019 | $3.23M | -64.0% |
| Q4 FY2018 | Dec 31, 2018 | $4.01M | +1.5% |
| Q3 FY2018 | Sep 30, 2018 | $15.03M | +140.6% |
| Q2 FY2018 | Jun 30, 2018 | $26.17M | +218.6% |
| Q1 FY2018 | Mar 31, 2018 | $8.99M | -16.2% |
| Q4 FY2017 | Dec 31, 2017 | $3.95M | -69.2% |
| Q3 FY2017 | Sep 30, 2017 | $6.25M | -58.9% |
| Q2 FY2017 | Jun 30, 2017 | $8.21M | -63.6% |
| Q1 FY2017 | Mar 31, 2017 | $10.73M | – |
| Q4 FY2016 | Dec 31, 2016 | $12.82M | – |
| Q3 FY2016 | Sep 30, 2016 | $15.21M | – |
| Q2 FY2016 | Jun 30, 2016 | $22.58M | – |
See a number that looks wrong?